Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MARKER THERAPEUTICS, INC.

(MRKR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Marker Therapeutics : to Present at the Virtual Raymond James Human Health Innovation Conference

06/16/2021 | 04:06pm EDT

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

A live webcast of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-raymond-james-human-health-innovation-conference-301314112.html

SOURCE Marker Therapeutics, Inc.


ę PRNewswire 2021
All news about MARKER THERAPEUTICS, INC.
07/28MARKER THERAPEUTICS : Announces Opening of New cGMP Manufacturing Facility (Form..
PU
07/28MARKER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
07/28MARKER THERAPEUTICS : Announces Opening of New cGMP Manufacturing Facility
PR
07/28Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
CI
07/06MARKER THERAPEUTICS : Completes Phase 2 Trial's Safety Lead-In Portion in Patien..
MT
07/06MARKER THERAPEUTICS : Announces Completion of Safety Lead-In Portion of Phase 2 ..
PU
07/06MARKER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
07/06MARKER THERAPEUTICS : Announces Completion of Safety Lead-In Portion of Phase 2 ..
PR
07/06Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2..
CI
06/25MARKER THERAPEUTICS, INC.(NASDAQGM : MRKR) dropped from Russell 2500 Value Index
CI
More news